According to the Complaint, TapImmune, Inc. is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious diseases.

On May 15, 2018, TapImmune issued a press release announcing the Merger Agreement with Marker Therapeutics, Inc. pursuant to which, Marker shareholders will receive (i) shares of TapImmune's common stock equal to the number of shares of TapImmune common stock issued and outstanding immediately prior to the effective time of the merger, and (ii) a number of warrants equal to the number of TapImmune warrants and stock options issued and outstanding immediately prior to the effective time of the merger (the "Merger
Consideration").

The Complaint alleges that on July 13, 2018, the Board authorized the filing of a materially incomplete and misleading Proxy Statement with the Securities and Exchange Commission, in violation of Sections 14(a) and 20(a) of the Exchange Act.

On November 6, 2018, this case was voluntarily dismissed as moot.